News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
682,864 Results
Type
Article (38954)
Company Profile (276)
Press Release (643634)
Section
Business (203814)
Career Advice (1985)
Deals (35356)
Drug Delivery (83)
Drug Development (80764)
Employer Resources (168)
FDA (16083)
Job Trends (14796)
News (344449)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1209)
Approvals (16002)
Artificial intelligence (112)
Bankruptcy (352)
Best Places to Work (11456)
Biotechnology (196)
Breast cancer (100)
Cancer (875)
Career advice (1657)
Cell therapy (191)
Clinical research (63867)
Collaboration (315)
Compensation (156)
COVID-19 (2520)
Cystic fibrosis (78)
Data (821)
Diabetes (126)
Diagnostics (6088)
Drug pricing (75)
Earnings (84051)
Employer resources (145)
Events (108729)
Executive appointments (238)
FDA (16506)
Funding (280)
Gene therapy (146)
GLP-1 (552)
Government (4316)
Healthcare (18647)
Infectious disease (2592)
Inflammatory bowel disease (101)
Interviews (308)
IPO (16263)
Job creations (3622)
Job search strategy (1415)
Layoffs (407)
Legal (7847)
Lung cancer (153)
Manufacturing (145)
Medical device (13136)
Medtech (13141)
Mergers & acquisitions (19097)
Metabolic disorders (345)
Neuroscience (1444)
NextGen Class of 2024 (6493)
Non-profit (4462)
Northern California (1161)
Obesity (207)
Opinion (175)
Patents (93)
People (56096)
Phase I (19808)
Phase II (28116)
Phase III (21001)
Pipeline (199)
Postmarket research (2553)
Preclinical (8422)
Radiopharmaceuticals (234)
Rare diseases (178)
Real estate (5888)
Regulatory (21421)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1050)
Startups (3560)
United States (11324)
Vaccines (532)
Weight loss (154)
Date
Today (178)
Last 7 days (823)
Last 30 days (2880)
Last 365 days (35990)
2024 (29970)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (186)
Asia (36989)
Australia (6033)
California (2637)
Canada (1152)
China (205)
Colorado (113)
Connecticut (116)
Europe (79186)
Florida (378)
Georgia (96)
Illinois (306)
Indiana (175)
Kansas (95)
Maryland (505)
Massachusetts (2140)
Michigan (142)
Minnesota (246)
New Jersey (801)
New York (813)
North Carolina (654)
Northern California (1161)
Ohio (123)
Pennsylvania (734)
South America (1091)
Southern California (1050)
Texas (366)
Utah (77)
Washington State (313)
682,864 Results for "evommune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio
Evommune, Inc. today announced it has entered into a definitive, worldwide license agreement with AprilBio Co., Ltd. (Kosdaq: 397030), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs, for an IL-18 targeted fusion protein.
June 24, 2024
·
3 min read
Press Releases
Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
September 3, 2024
·
3 min read
Business
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
Evommune, Inc. and Accutar Biotechnology Inc. today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.
November 28, 2023
·
2 min read
Business
Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Greater China and key Asian countries
Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.
March 20, 2024
·
3 min read
Drug Development
Evommune Announces Initiation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria
Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the initiation of its Phase 1 first-in-human study, evaluating EVO756 in heathy adults and adults with chronic spontaneous urticaria (CSU).
January 18, 2024
·
3 min read
Press Releases
Evommune Announces Positive Proof-of-Concept Clinical Trial Results for its MRGPRX2 Antagonist (EVO756)
July 16, 2024
·
3 min read
Business
Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan
Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan.
September 27, 2023
·
4 min read
Business
Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team
Evommune, Inc. today announced the closing of an additional $7.5 million to its Series B financing from new investor Verition Fund Management, bringing the total raised in the Series B round to $57.5 million.
June 28, 2023
·
2 min read
Biotech Bay
Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases
Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the completion of a $50 million Series B financing.
April 26, 2023
·
2 min read
Drug Development
Evommune’s Human Tissue-based Approach Enables Discovery and Development of Safer, Innovative Chronic Inflammation Therapies
Evommune’s novel human tissue-based assay system is proving to be a key differentiator as the company develops therapies to control chronic inflammation in autoimmune diseases.
October 7, 2022
·
7 min read
·
Gail Dutton
1 of 68,287
Next
